NRG-BR002

A phase IIR/III Trial of Standard of Care Therapy with or without stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

Additional Information

Study Location:
Owensboro Health
Mitchell Memorial Cancer Center
1020 Breckenridge Street
Owensboro, KY 42303
Cancer Type: Breast Cancer
Purpose:
Phase II-R: The primary objective of this study is to determine whether ablation (through SBRT and/or
surgical resection of all known metastases) in oligometastatic breast cancer patients provides a
sufficient signal for improved progression-free survival (PFS) to warrant full accrual to Phase III portion
of the trial
Phase III: To determine whether ablation (through SBRT and/or surgical resection of all known
metastases) in oligometastatic breast cancer patients significantly improve overall survival (OS)
Enrollment and Eligibility:
Age: 18 years or older
Gender: Female
Disease:
• Pathologically confirmed metastatic breast cancer
• Less than or equal to 2 metastases seen on standard imaging
• Maximum diameter of individual metastasis in any dimension less than or equal to 5 cm
• Metastases must be 5 cm away from each other
• Patients must be registered with 365 of the initial metastatic breast cancer diagnosis.
Contact Person: Judy Strobel RN, BSN, OCN, CCRP  

                      Robin Osborne

Clinical Research Specialist
Phone: 270-691-8094/270-688-1938
Fax: 270-688-3673
Email: Judith.strobel@owensborohealth.org

IRB Protocol Number
14383177.0